Baxter International Inc.
Income Statement
| Line Item | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|
| Revenue | $12.84B | $12.56B | $12.35B | $11.26B |
| Renal | — | — | — | — |
| Hospital Products | — | — | — | — |
| Americas | — | — | — | — |
| EMEA | — | — | — | — |
| APAC | — | — | — | — |
| Hillrom | — | — | — | — |
| Medical Products and Therapies | — | — | — | — |
| Healthcare Systems and Technologies | — | — | — | — |
| Pharmaceuticals | — | — | — | — |
| Kidney Care | — | — | — | — |
| Other | — | — | — | — |
| Cost of Revenue | $6.89B | $6.04B | $6.22B | $5.74B |
| Gross Profit | $5.96B | $6.53B | $6.13B | $5.52B |
| Gross Margin | 46.4% | 51.9% | 49.6% | 49.0% |
| Operating Expenses | ||||
| Research & Development | $915.0M | $917.0M | $868.0M | $760.0M |
| SG&A Expense | $2.91B | $2.73B | $2.70B | $2.52B |
| Operating Income | $2.01B | $2.85B | $2.61B | $2.13B |
| Operating Margin | 15.6% | 22.7% | 21.1% | 18.9% |
| Interest Expense | $115.0M | $117.0M | $148.0M | — |
| Pretax Income | $1.89B | $2.73B | $2.46B | $2.13B |
| Income Tax Expense | $463.0M | $519.0M | $437.0M | $407.0M |
| Net Income | $1.42B | $2.21B | $2.01B | $1.71B |
| Net Margin | 11.1% | 17.6% | 16.3% | 15.2% |
| EPS (Basic) | $2.41 | $3.63 | $3.22 | $2.65 |
| EPS (Diluted) | $2.39 | $3.59 | $3.16 | $2.61 |
| Shares Outstanding (Basic) | 590.0M | 607.0M | 625.0M | 644.0M |
| Shares Outstanding (Diluted) | 594.0M | 614.0M | 637.0M | 654.0M |
| Dividends Per Share | $1.18 | $1.07 | $0.91 | $0.72 |